Hearing Changes in HIV Patients Starting Zidovudine or Didanosine
Author Information
Author(s): Schouten Jeffrey T, Lockhart David W, Rees Thomas S, Collier Ann C, Marra Christina M
Primary Institution: University of Washington
Hypothesis
Does treatment with zidovudine (ZDV) or didanosine (ddI) cause hearing loss in treatment-naïve HIV-infected individuals?
Conclusion
The study found that treatment with ZDV and ddI did not result in hearing loss over 32 weeks.
Supporting Evidence
- Subjects were well balanced regarding baseline hearing in the ZDV versus ddI exposure group.
- At study entry, 22 of 33 subjects had a hearing level greater than 25 dB at one or more frequencies.
- Overall, there was a trend towards improvement in hearing, but it did not reach statistical significance.
Takeaway
This study looked at whether two HIV medications hurt people's hearing, and it found that they didn't.
Methodology
A prospective observational pilot study measuring hearing changes at baseline, 16, and 32 weeks after starting antiretroviral therapy.
Potential Biases
Potential bias due to the non-randomized design and the small number of participants.
Limitations
Small sample size, lack of randomization, short follow-up duration, and absence of a control group.
Participant Demographics
Primarily gay, white men with a mean age of 35.3 years.
Statistical Information
Statistical Significance
p>0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website